Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future

Revkin, James H.; Shear, Charles L.; Pouleur, H.; Ryder, Steven W.; Orloff, David G.

doi:10.1124/pr.59.1.1

Cited by 63 publications

(52 citation statements)

References 88 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 There are several lines of evidence to suggest that the rate of change in CIMT over time is a good atherosclerosis end point. [7][8][9] Also for plaques, recent evidence emerged to suggest that change over time can be readily and reliably assessed. 6 Likewise a second ancillary study of PERFORM (748 patients included to investigate the evolution of MRI lesions) failed to demonstrate the progression of fluid attenuated inversion recovery imaged lesions, brain or hippocampal volumes, or emergent microbleeds.…”

Section: Discussionmentioning

confidence: 99%

“…The rate of change in CIMT over time has been used as a primary outcome measure in a large number of randomized trials to assess the effect of an intervention on atherosclerosis progression. [1][2][3][4][5][6][7][8][9] Similarly, change in plaque occurrence over time has been shown to be a suitable outcome measurement in trials. 6 We, therefore, set out to assess the antiatherosclerotic properties of Terutroban in a dedicated vascular study, nested in the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) trial.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin

Bots

Ford

Lloyd

et al. 2014

Stroke

View full text Add to dashboard Cite

Background and Purpose-Thromboxane prostaglandin receptors have been implicated to be involved in the atherosclerotic process. We assessed whether Terutroban, a thromboxane prostaglandin receptor antagonist, affects the progression of atherosclerosis, as measured by common carotid intima-media thickness and carotid plaques. Methods-A substudy was performed among 1141 participants of the aspirin-controlled Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) trial. Common carotid intima-media thickness and carotid plaque occurrence was measured during a 3-year period. Results-Baseline characteristics did not differ between Terutroban (n=592) and aspirin (n=549) treated patients and were similar as in the main study. Mean study and treatment duration were similar (28 and 25 months, respectively). In the Terutroban group, the annualized rate of change in common carotid intima-media thickness was 0.006 mm per year (95% confidence interval, -0.004 to 0.016) and -0.005 mm per year (95% confidence interval, -0.015 to 0.005) in the aspirin group. There was no statistically significant difference between the groups in the annualized rate of change of common carotid intima-media thickness (0.011 mm per year; 95% confidence interval, −0.003 to 0.025). At 12 months of follow-up, 66% of Terutroban patients had no emergent plaques, 31% had 1 to 2 emergent plaques, and 3% had ≥3 emergent plaques. In the aspirin group, the corresponding percentages were 64%, 32%, and 4%. Over time, there was no statistically significant difference in the number of emergent carotid plaques between treatment modalities (rate ratio, 0.91; 95% confidence interval, 0.77-1.07). Conclusions-Compared with aspirin, Terutroban did not beneficially affect progression of carotid atherosclerosis among well-treated patients with a history of ischemic stroke or transient ischemic attacks with an internal carotid stenosis <70%. Clinical Trial Registration-URL: http://www.controlled-trials.com. Unique identifier: ISRCTN66157730.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin

Bots

Ford

Lloyd

et al. 2014

Stroke

View full text Add to dashboard Cite

show abstract

“…The assessment of endothelium-dependent vasodilatation is widely used to evaluate endothelial function [25,26]. Measurements of the brachial artery diameter before and after an increase in shear stress induced by reactive hyperemia (ie, FMD) is most frequently used in the clinical setting [27,28]. During the vasodilation caused by increased shear stress in walls and by reactive hyperemia, which activates release on eNOS and increases NO production in the endothelium.…”

Section: Non-invasive Methods Of Assessing Vascular Functionsmentioning

confidence: 99%

The Role of Noninvasive Imaging for Detection High Risk Patients with Subclinical Atherosclerosis

Hristova¹

2016

Arch Clin Hypertens

View full text Add to dashboard Cite

Non-invasive imaging is widely used to assess vascular dysfunction, including measurement of flow-mediated vasodilatation of the brachial artery (FMD), pulse wave velocity (PWV), the augmentation index (AI), and central blood pressure. Endothelial dysfunction, a main contributor of atherosclerosis is possible diagnostic tool by FMD. An arterial stiffness, assessing by the PWV and/or arterial dispensability and beta stiffness index have been associated with cardiovascular risk. Ultrasound-based methods are used to assess elastic properties of the arterial walls in studies of arterial stiffness and atherosclerosis. In asymptomatic individuals is essential in order to detect, predict and prevent cardiovascular diseases first be estimated based on the global assessment of risk factors? Nowadays is recommended in daily routine screening for coronary artery disease in asymptomatic individuals with intermediate (10-20% 10-year risk of coronary artery disease) or high risk (>20% 10-year risk of coronary artery disease) to provide a further screening.

show abstract

“…While LDL cholesterol is a major health factor, here are a few other factors that can contribute to the progression of athero. The need for more rapid drug development highlights the role that surrogate markers may play in establishing the efficacy of drugs for managing CVD, and more specifically, atherosclerosis (Revkin et al 2007). …”

Section: Cholesterolmentioning

confidence: 99%

Atherosclerosis and Antihyperlipidemic Agents

Gad¹

2012

Medicinal Chemistry and Drug Design

View full text Add to dashboard Cite

Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future

Cited by 63 publications

References 88 publications

Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin

Thromboxane Prostaglandin Receptor Antagonist and Carotid Atherosclerosis Progression in Patients With Cerebrovascular Disease of Ischemic Origin

The Role of Noninvasive Imaging for Detection High Risk Patients with Subclinical Atherosclerosis

Atherosclerosis and Antihyperlipidemic Agents

Contact Info

Product

Resources

About